> top > docs > PubMed:26546614 > annotations

PubMed:26546614 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 0-15 D048948 denotes 14-3-3 Proteins
T3 32-37 PR:Q5S006 denotes LRRK2
T4 32-37 PR:000003033 denotes LRRK2
T5 32-37 PR:Q5S007 denotes LRRK2
T6 38-53 GO:0016301 denotes kinase activity
T7 58-65 GO:0043005 denotes neurite
T9 91-98 6308 denotes leucine
T10 91-98 SO:0001437 denotes leucine
T8 91-98 CHEBI:15603 denotes leucine
T11 91-98 D007930 denotes leucine
T12 91-98 CHEBI:25017 denotes leucine
T13 91-98 D007930 denotes leucine
T14 104-110 SO:0001068 denotes repeat
T15 121-126 PR:Q5S006 denotes LRRK2
T16 121-126 PR:000003033 denotes LRRK2
T17 121-126 PR:Q5S007 denotes LRRK2
T22 173-192 D010300 denotes Parkinson's disease
T23 173-192 D010300 denotes Parkinson's disease
T26 203-208 PR:Q5S006 denotes LRRK2
T27 203-208 PR:000003033 denotes LRRK2
T28 203-208 PR:Q5S007 denotes LRRK2
T29 249-254 PR:Q5S006 denotes LRRK2
T30 249-254 PR:000003033 denotes LRRK2
T31 249-254 PR:Q5S007 denotes LRRK2
T32 267-276 SO:0000119 denotes regulated
T33 322-331 SO:0000856 denotes conserved
T34 332-347 D048948 denotes 14-3-3 proteins
T36 408-418 GO:0008219 denotes cell death
T37 453-458 PR:Q5S006 denotes LRRK2
T38 453-458 PR:000003033 denotes LRRK2
T39 453-458 PR:Q5S007 denotes LRRK2
T40 527-532 PR:Q5S006 denotes LRRK2
T41 527-532 PR:000003033 denotes LRRK2
T42 527-532 PR:Q5S007 denotes LRRK2
T43 541-548 GO:0043005 denotes neurite
T44 564-579 GO:0016301 denotes kinase activity
T45 624-631 GO:0043005 denotes neurite
T46 663-666 SO:0000153 denotes BAC
T47 667-677 SO:0000781 denotes transgenic
T48 685-690 PR:Q5S006 denotes LRRK2
T49 685-690 PR:000003033 denotes LRRK2
T50 685-690 PR:Q5S007 denotes LRRK2
T51 691-695 PR:000005054 denotes mice
T53 691-695 O89094 denotes mice
T52 691-695 D051379 denotes mice
T54 691-695 10095 denotes mice
T55 713-722 SO:0000817 denotes wild-type
T56 774-781 GO:0043005 denotes neurite
T57 819-822 SO:0000153 denotes BAC
T58 823-833 SO:0000781 denotes transgenic
T59 841-846 PR:Q5S006 denotes LRRK2
T60 841-846 PR:000003033 denotes LRRK2
T61 841-846 PR:Q5S007 denotes LRRK2
T62 847-851 PR:000005054 denotes mice
T64 847-851 O89094 denotes mice
T63 847-851 D051379 denotes mice
T65 847-851 10095 denotes mice
T66 894-897 PR:Q8UVK2 denotes pan
T67 905-914 CHEBI:35222 denotes inhibitor
T68 915-923 C443131 denotes difopein
T69 927-944 SO:0002052 denotes dominant-negative
T70 969-976 GO:0043005 denotes neurite
T71 994-999 PR:Q5S006 denotes LRRK2
T72 994-999 PR:000003033 denotes LRRK2
T73 994-999 PR:Q5S007 denotes LRRK2
T74 1023-1028 PR:Q5S006 denotes LRRK2
T75 1023-1028 PR:000003033 denotes LRRK2
T76 1023-1028 PR:Q5S007 denotes LRRK2
T77 1075-1090 GO:0016301 denotes kinase activity
T78 1125-1130 PR:Q5S006 denotes LRRK2
T79 1125-1130 PR:000003033 denotes LRRK2
T80 1125-1130 PR:Q5S007 denotes LRRK2
T81 1131-1146 GO:0016301 denotes kinase activity
T82 1183-1198 GO:0016301 denotes kinase activity
T83 1209-1214 PR:Q5S006 denotes LRRK2
T84 1209-1214 PR:000003033 denotes LRRK2
T85 1209-1214 PR:Q5S007 denotes LRRK2
T86 1222-1230 C443131 denotes difopein
T87 1244-1259 GO:0016301 denotes kinase activity
T88 1270-1275 PR:Q5S006 denotes LRRK2
T89 1270-1275 PR:000003033 denotes LRRK2
T90 1270-1275 PR:Q5S007 denotes LRRK2
T91 1310-1315 PR:Q5S006 denotes LRRK2
T92 1310-1315 PR:000003033 denotes LRRK2
T93 1310-1315 PR:Q5S007 denotes LRRK2
T94 1316-1331 GO:0016301 denotes kinase activity
T95 1348-1355 SO:0100018 denotes binding
T96 1348-1355 SO:0001091 denotes binding
T97 1348-1355 GO:0005488 denotes binding
T98 1372-1377 PR:Q5S006 denotes LRRK2
T99 1372-1377 PR:000003033 denotes LRRK2
T100 1372-1377 PR:Q5S007 denotes LRRK2
T101 1399-1406 GO:0043005 denotes neurite
T102 1421-1429 C443131 denotes difopein
T103 1440-1445 PR:Q5S006 denotes LRRK2
T104 1440-1445 PR:000003033 denotes LRRK2
T105 1440-1445 PR:Q5S007 denotes LRRK2
T106 1470-1475 PR:Q5S006 denotes LRRK2
T107 1470-1475 PR:000003033 denotes LRRK2
T108 1470-1475 PR:Q5S007 denotes LRRK2
T109 1483-1493 CHEBI:35222 denotes inhibitors
T110 1549-1554 PR:Q5S006 denotes LRRK2
T111 1549-1554 PR:000003033 denotes LRRK2
T112 1549-1554 PR:Q5S007 denotes LRRK2
T113 1589-1594 PR:Q5S006 denotes LRRK2
T114 1589-1594 PR:000003033 denotes LRRK2
T115 1589-1594 PR:Q5S007 denotes LRRK2
T116 1605-1614 MOP:0000569 denotes reduction
T117 1618-1633 GO:0016301 denotes kinase activity

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-77 DRI_Background denotes 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
T2 78-244 DRI_Approach denotes Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of inherited Parkinson's disease (PD), and LRRK2 is a risk factor for idiopathic PD.
T3 245-300 DRI_Background denotes How LRRK2 function is regulated is not well understood.
T4 301-459 DRI_Background denotes Recently, the highly conserved 14-3-3 proteins, which play a key role in many cellular functions including cell death, have been shown to interact with LRRK2.
T5 460-580 DRI_Approach denotes In this study, we investigated whether 14-3-3s can regulate mutant LRRK2-induced neurite shortening and kinase activity.
T6 581-730 DRI_Background denotes In the presence of 14-3-3θ overexpression, neurite length of primary neurons from BAC transgenic G2019S-LRRK2 mice returned back to wild-type levels.
T7 731-852 DRI_Background denotes Similarly, 14-3-3θ overexpression reversed neurite shortening in neuronal cultures from BAC transgenic R1441G-LRRK2 mice.
T8 853-926 DRI_Background denotes Conversely, inhibition of 14-3-3s by the pan-14-3-3 inhibitor difopein or
T9 927-952 Token_Label.OUTSIDE denotes dominant-negative 14-3-3θ
T10 953-1009 DRI_Background denotes further reduced neurite length in G2019S-LRRK2 cultures.
T11 1010-1147 DRI_Background denotes Since G2019S-LRRK2 toxicity is likely mediated through increased kinase activity, we examined 14-3-3θ's effects on LRRK2 kinase activity.
T12 1148-1276 DRI_Background denotes 14-3-3θ overexpression reduced the kinase activity of G2019S-LRRK2, while difopein promoted the kinase activity of G2019S-LRRK2.
T13 1277-1378 DRI_Challenge denotes The ability of 14-3-3θ to reduce LRRK2 kinase activity required direct binding of 14-3-3θ with LRRK2.
T14 1379-1494 DRI_Background denotes The potentiation of neurite shortening by difopein in G2019S-LRRK2 neurons was reversed by LRRK2 kinase inhibitors.
T15 1495-1634 DRI_Approach denotes Taken together, we conclude that 14-3-3θ can regulate LRRK2 and reduce the toxicity of mutant LRRK2 through a reduction of kinase activity.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 78-244 DRI_Approach denotes Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of inherited Parkinson's disease (PD), and LRRK2 is a risk factor for idiopathic PD.
T2 245-300 DRI_Background denotes How LRRK2 function is regulated is not well understood.
T3 301-459 DRI_Background denotes Recently, the highly conserved 14-3-3 proteins, which play a key role in many cellular functions including cell death, have been shown to interact with LRRK2.
T4 460-580 DRI_Approach denotes In this study, we investigated whether 14-3-3s can regulate mutant LRRK2-induced neurite shortening and kinase activity.
T5 581-730 DRI_Background denotes In the presence of 14-3-3θ overexpression, neurite length of primary neurons from BAC transgenic G2019S-LRRK2 mice returned back to wild-type levels.
T6 731-852 DRI_Background denotes Similarly, 14-3-3θ overexpression reversed neurite shortening in neuronal cultures from BAC transgenic R1441G-LRRK2 mice.
T7 853-926 DRI_Background denotes Conversely, inhibition of 14-3-3s by the pan-14-3-3 inhibitor difopein or
T8 953-1009 DRI_Background denotes further reduced neurite length in G2019S-LRRK2 cultures.
T9 1010-1147 DRI_Background denotes Since G2019S-LRRK2 toxicity is likely mediated through increased kinase activity, we examined 14-3-3θ's effects on LRRK2 kinase activity.
T10 1148-1276 DRI_Background denotes 14-3-3θ overexpression reduced the kinase activity of G2019S-LRRK2, while difopein promoted the kinase activity of G2019S-LRRK2.
T11 1277-1378 DRI_Challenge denotes The ability of 14-3-3θ to reduce LRRK2 kinase activity required direct binding of 14-3-3θ with LRRK2.
T12 1379-1494 DRI_Background denotes The potentiation of neurite shortening by difopein in G2019S-LRRK2 neurons was reversed by LRRK2 kinase inhibitors.
T13 1495-1634 DRI_Approach denotes Taken together, we conclude that 14-3-3θ can regulate LRRK2 and reduce the toxicity of mutant LRRK2 through a reduction of kinase activity.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
26546614-1#13#41#gene120892 91-119 gene120892 denotes leucine-rich repeat kinase 2
26546614-1#43#48#gene120892 121-126 gene120892 denotes LRRK2
26546614-1#125#130#gene120892 203-208 gene120892 denotes LRRK2
26546614-1#95#114#diseaseC0030567 173-192 diseaseC0030567 denotes Parkinson's disease
26546614-1#116#118#diseaseC0030567 194-196 diseaseC0030567 denotes PD
26546614-1#163#165#diseaseC0030567 241-243 diseaseC0030567 denotes PD
26546614-1#95#114#diseaseC0030567 173-192 diseaseC0030567 denotes Parkinson's disease
26546614-1#116#118#diseaseC0030567 194-196 diseaseC0030567 denotes PD
26546614-1#163#165#diseaseC0030567 241-243 diseaseC0030567 denotes PD
26546614-1#95#114#diseaseC0030567 173-192 diseaseC0030567 denotes Parkinson's disease
26546614-1#116#118#diseaseC0030567 194-196 diseaseC0030567 denotes PD
26546614-1#163#165#diseaseC0030567 241-243 diseaseC0030567 denotes PD
13#41#gene12089295#114#diseaseC0030567 26546614-1#13#41#gene120892 26546614-1#95#114#diseaseC0030567 associated_with leucine-rich repeat kinase 2,Parkinson's disease
13#41#gene120892116#118#diseaseC0030567 26546614-1#13#41#gene120892 26546614-1#116#118#diseaseC0030567 associated_with leucine-rich repeat kinase 2,PD
13#41#gene120892163#165#diseaseC0030567 26546614-1#13#41#gene120892 26546614-1#163#165#diseaseC0030567 associated_with leucine-rich repeat kinase 2,PD
13#41#gene12089295#114#diseaseC0030567 26546614-1#13#41#gene120892 26546614-1#95#114#diseaseC0030567 associated_with leucine-rich repeat kinase 2,Parkinson's disease
13#41#gene120892116#118#diseaseC0030567 26546614-1#13#41#gene120892 26546614-1#116#118#diseaseC0030567 associated_with leucine-rich repeat kinase 2,PD
13#41#gene120892163#165#diseaseC0030567 26546614-1#13#41#gene120892 26546614-1#163#165#diseaseC0030567 associated_with leucine-rich repeat kinase 2,PD
13#41#gene12089295#114#diseaseC0030567 26546614-1#13#41#gene120892 26546614-1#95#114#diseaseC0030567 associated_with leucine-rich repeat kinase 2,Parkinson's disease
13#41#gene120892116#118#diseaseC0030567 26546614-1#13#41#gene120892 26546614-1#116#118#diseaseC0030567 associated_with leucine-rich repeat kinase 2,PD
13#41#gene120892163#165#diseaseC0030567 26546614-1#13#41#gene120892 26546614-1#163#165#diseaseC0030567 associated_with leucine-rich repeat kinase 2,PD
43#48#gene12089295#114#diseaseC0030567 26546614-1#43#48#gene120892 26546614-1#95#114#diseaseC0030567 associated_with LRRK2,Parkinson's disease
43#48#gene120892116#118#diseaseC0030567 26546614-1#43#48#gene120892 26546614-1#116#118#diseaseC0030567 associated_with LRRK2,PD
43#48#gene120892163#165#diseaseC0030567 26546614-1#43#48#gene120892 26546614-1#163#165#diseaseC0030567 associated_with LRRK2,PD
43#48#gene12089295#114#diseaseC0030567 26546614-1#43#48#gene120892 26546614-1#95#114#diseaseC0030567 associated_with LRRK2,Parkinson's disease
43#48#gene120892116#118#diseaseC0030567 26546614-1#43#48#gene120892 26546614-1#116#118#diseaseC0030567 associated_with LRRK2,PD
43#48#gene120892163#165#diseaseC0030567 26546614-1#43#48#gene120892 26546614-1#163#165#diseaseC0030567 associated_with LRRK2,PD
43#48#gene12089295#114#diseaseC0030567 26546614-1#43#48#gene120892 26546614-1#95#114#diseaseC0030567 associated_with LRRK2,Parkinson's disease
43#48#gene120892116#118#diseaseC0030567 26546614-1#43#48#gene120892 26546614-1#116#118#diseaseC0030567 associated_with LRRK2,PD
43#48#gene120892163#165#diseaseC0030567 26546614-1#43#48#gene120892 26546614-1#163#165#diseaseC0030567 associated_with LRRK2,PD
125#130#gene12089295#114#diseaseC0030567 26546614-1#125#130#gene120892 26546614-1#95#114#diseaseC0030567 associated_with LRRK2,Parkinson's disease
125#130#gene120892116#118#diseaseC0030567 26546614-1#125#130#gene120892 26546614-1#116#118#diseaseC0030567 associated_with LRRK2,PD
125#130#gene120892163#165#diseaseC0030567 26546614-1#125#130#gene120892 26546614-1#163#165#diseaseC0030567 associated_with LRRK2,PD
125#130#gene12089295#114#diseaseC0030567 26546614-1#125#130#gene120892 26546614-1#95#114#diseaseC0030567 associated_with LRRK2,Parkinson's disease
125#130#gene120892116#118#diseaseC0030567 26546614-1#125#130#gene120892 26546614-1#116#118#diseaseC0030567 associated_with LRRK2,PD
125#130#gene120892163#165#diseaseC0030567 26546614-1#125#130#gene120892 26546614-1#163#165#diseaseC0030567 associated_with LRRK2,PD
125#130#gene12089295#114#diseaseC0030567 26546614-1#125#130#gene120892 26546614-1#95#114#diseaseC0030567 associated_with LRRK2,Parkinson's disease
125#130#gene120892116#118#diseaseC0030567 26546614-1#125#130#gene120892 26546614-1#116#118#diseaseC0030567 associated_with LRRK2,PD
125#130#gene120892163#165#diseaseC0030567 26546614-1#125#130#gene120892 26546614-1#163#165#diseaseC0030567 associated_with LRRK2,PD